Expert Ratings For Blueprint Medicines
Expert Ratings For Blueprint Medicines
Blueprint Medicines的专家评级
During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.
在过去的三个月中，有17名分析师分享了他们对 Blueprint Medicines（纳斯达克：BPMC）的评估，展示了从看好到看淡的不同观点。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
总结他们最近的评估，下表展示了过去30天内不断变化的情绪，并将其与之前的几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positive shift, the current average has risen by 14.52% from the previous average price target of $101.60.
在12个月价格目标的评估中，分析师揭示了 Blueprint Medicines 的见解，呈现出平均目标为116.35美元，最高估价为168.00美元，最低估价为75.00美元。目前的平均数已比先前的平均价格目标101.60美元上涨了14.52%。
Investigating Analyst Ratings: An Elaborate Study
分析师评级的调查：一项详尽的研究
The standing of Blueprint Medicines among financial...
最近分析师行动...
登录免费看全文
登录/注册